- Previous Close
0.2650 - Open
0.2500 - Bid 0.2450 x --
- Ask 0.2550 x --
- Day's Range
0.2450 - 0.2550 - 52 Week Range
0.2350 - 0.3400 - Volume
209,300 - Avg. Volume
340,886 - Market Cap (intraday)
212.393M - Beta (5Y Monthly) -0.05
- PE Ratio (TTM)
25.50 - EPS (TTM)
0.0100 - Earnings Date --
- Forward Dividend & Yield 0.01 (4.71%)
- Ex-Dividend Date Feb 12, 2025
- 1y Target Est
--
Cengild Medical Berhad, an investment holding company, operates a medical center in Malaysia. The company offers various care and treatment consultant services for gastrointestinal and liver diseases, morbid obesity, and oncology and urological conditions; general cardiology and gynecology assessment; gastroenterology and hepatology; anesthesiology, endocrinology, general surgery, internal medicine, orthopedic, plastic and reconstructive surgery, radiology, rheumatology, and thoracic surgery; ear, nose and throat; gastrointestinal surgeries, including upper gastrointestinal, hepatobiliary, pancreatic, colorectal surgery, and bariatric surgery; and chemotherapy. It also provides medical management services; nursing services and clinical support services; clinical laboratory and pharmacy; radiology and imaging services; dietetics and nutrition, physiotherapy, and medical record services; accident and emergency care, and health screenings; and consultant services. Cengild Medical Berhad was founded in 2017 and is based in Kuala Lumpur, Malaysia.
cengild.comRecent News: 0243.KL
View MorePerformance Overview: 0243.KL
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is FTSE Bursa Malaysia KLCI (^KLSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0243.KL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0243.KL
View MoreValuation Measures
Market Cap
212.39M
Enterprise Value
150.34M
Trailing P/E
18.48
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.81
Price/Book (mrq)
1.84
Enterprise Value/Revenue
1.99
Enterprise Value/EBITDA
6.57
Financial Highlights
Profitability and Income Statement
Profit Margin
15.20%
Return on Assets (ttm)
5.21%
Return on Equity (ttm)
10.23%
Revenue (ttm)
75.66M
Net Income Avi to Common (ttm)
11.5M
Diluted EPS (ttm)
0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
94.7M
Total Debt/Equity (mrq)
28.32%
Levered Free Cash Flow (ttm)
-26.69M